Clovis Oncology, Inc. (CLVS): Debt Offering News

CLVS – Company intends to offer, subject to market and other conditions, $200 million aggregate principal amount of its convertible senior notes due 2025 in an underwritten registered public offering.

Key Facts Surrounding This News Item

  • CLVS had a POWR Rating of D (Sell) coming into today.
  • CLVS was 7.20% above its 10-Day Moving Average coming into today.
  • CLVS was 7.70% above its 20-Day Moving Average coming into today.
  • CLVS was 6.94% above its 50-Day Moving Average coming into today.
  • CLVS was 2.06% above its 100-Day Moving Average coming into today.
  • CLVS was -12.14% below its 200-Day Moving Average coming into today.
  • CLVS had returned -10.82% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Clovis Oncology, Inc. (CLVS)

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The company was founded in 2009 and is based in Boulder, Colorado. View our full CLVS ticker page with ratings, news, and more.

CLVS at a Glance

CLVS Current POWR Rating™
Overall POWR Rating™
CLVS Current Price $22.94 0.43%
More CLVS Ratings, Data, and News

CLVS Price Reaction

The day of this event (Apr. 16, 2018)
CLVS Closing Price$54.41 10.27%
CLVS Volume2,841,400
89.51% from avg
Leading up to this event
CLVS 1-mo return3.27%
After this event
CLVS 1-day return13.84%
CLVS 3-day return18.16%
CLVS 5-day return25.39%

CLVS Price Chart

More Clovis Oncology, Inc. (CLVS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLVS News
Page generated in 0.9282 seconds.